(Press-News.org) Medication-assisted treatment, or MAT, is an important tool in the ongoing fight against opioid use dependence in the United States. Employing certain medications in combination with counseling and behavioral therapy, MAT offers a comprehensive, "whole-patient" approach to addressing opioid use.
According to a new study from researchers at the UConn School of Social Work and the Connecticut Department of Mental Health and Addiction Services, Connecticut's MAT programs have higher-than-average patient retention rates - more people who enter Connecticut's programs stay in the program to completion.
But the study - recently published in the journal Substance Use and Misuse - also found that younger patients and patients who reported cocaine or crack use in addition to opioid dependence had a harder time sticking with the MAT treatment program than those who were older or those who might also be using other substances, which has implications for both program providers and policymakers as the country continues to grapple with the opioid epidemic.
"One of the things you look at when folks are coming into a program like this is what kinds of drugs they were using right before this started," says Michael Fendrich, a professor and associate dean for research at the School of Social Work who focuses on policies, services, interventions, and risk factors related to substance misuse and mental health and is the lead author of the new study. "A lot of programs are focused on one substance, but a lot of folks come in there not just using one substance."
The study looked at information about clients enrolled in four federally funded MAT programs in Connecticut over a three-year period, from December 2016 to August 2019, and included 423 clients that followed the same treatment model. In addition to medication, the programs included cognitive behavioral therapy and employed a recovery support coach - a person in recovery from opioid use disorder - as part of the treatment model.
Clients were considered to be "retained" if they were still receiving services from the program at the six-month interview or if they had a successful discharge before the six-month interview. The researchers found that, at six months, 58.9% of participants has been retained in the program. Most of these participants - 71% - were still receiving services. Others had completed services or had successful discharges at six-month follow-ups.
Prior use of other substances did not necessarily lead to lower retention - a finding that Fendrich says he found surprising. In particular, those who reported using benzodiazapines actually had a higher probability of success in the program.
"I don't have a solid reason for that," Fendrich says, "but we do know that benzodiazapine is a dangerous medication to be taken at the same time that you're taking opioid treatment medications, so there might have been a little bit more focus on making sure that those folks were using the treatment medication in the way they were supposed to be using it."
But reported cocaine or crack use was correlated with reduced retention, an area that Fendrich says merits greater study.
"Prior substance use is a complex issue," he says. "You can't just say, 'all prior drug use is going to decrease the chances for success.' But you need to look at what specific drugs are being used. And I would suggest that we just need some more follow up on that one."
Overall, rates of retention did not vary despite differences in location and in the demographics of the clients who sought treatment at the four sites.
"They were dealing with diverse clients, and they were pretty similar kinds of outcomes that they experienced," Fendrich says, "which speaks highly to the implementation of the program in the state."
Demographics, though, did influence success: older clients had higher retention rates than younger clients, suggesting that strategies specifically designed to support younger people who are struggling with opioid dependence are needed.
"I really think that the emerging adult, young adult, group is a group that's at risk for so many things, and I think we need to think about them in an even more focused way," Fendrich says. "As we emerge from the pandemic, this is a group that's struggling on many issues. It's a really difficult time, in terms of employment opportunities, in development - folks are not stabilized in their life - in relationships, and in just general direction in life. And so, it becomes harder when there's also substance dependence that's added into the picture."
While the role of peers employed as recovery support coaches in Connecticut's program was not specifically evaluated as part of the study, the researchers suggested their participation in the treatment model could contribute to Connecticut's higher retention rates. This hypothesis was supported by focus groups the researchers conducted with the program clients; many of the client comments were about the importance of peer support. While not unique to Connecticut, use of recovery support coaches in MAT programs is not universal, Fendrich says.
Programs need to think about the potential unique needs of people coming into the program, he notes, and look comprehensively at supports they might need to be successful.
"It's never just one thing," Fendrich says. "You know, people are complicated. And there is an opioid crisis, but folks who are who are dependent on opioids have lots of other problems. Some are addiction-related, and some are more in what I call the 'psychosocial adjustment realm,' but they all need attention. I think we've been good at attending to those in our programs in Connecticut, and it's a real feather in our cap."
He continues, "We have great programs here in the state, and we'll hopefully continue to build on the success that we've seen in our programs so far. But policy-wise, we need to be comprehensive in our approach to treatment for people who are coming into programs with opioid dependence."
INFORMATION:
Fendrich's co-Investigator on the study was Eleni Rodis, managing director of the research division at the Connecticut Department of Mental Health and Addiction Services (DMHAS). Other collaborators on the study include Jessica Becker, a research assistant in the UConn School of Social Work, as well as Melissa Ives and Martha Marin, who are jointly based at the School of Social Work and the DMHAS research division.
This study was supported through programmatic funding from the federal Substance Abuse and Mental Health Services Administration.
Philadelphia, May 18, 2021 - Throughout the COVID-19 pandemic, supply chain shortages of reagents and test kits have limited the rapid expansion of clinical testing needed to contain the virus. Investigators have developed and validated a new microchip real-time technology platform that uses 10-fold less reagents compared to Centers for Disease Control and Prevention (CDC)-approved tube-based RT-PCR tests, and reports results in as little as 30 minutes. Its accuracy was 100 percent predictive in clinical samples, investigators explain in the Journal of Molecular Diagnostics, published by Elsevier.
"Sensitivity is critical for early detection of COVID-19 ...
Classic computers use binary values (0/1) to perform. By contrast, our brain cells can use more values to operate, making them more energy-efficient than computers. This is why scientists are interested in neuromorphic (brain-like) computing. Physicists from the University of Groningen (the Netherlands) have used a complex oxide to create elements comparable to the neurons and synapses in the brain using spins, a magnetic property of electrons. Their results were published on 18 May in the journal Frontiers in Nanotechnology.
Although computers can do straightforward calculations much faster than humans, our brains outperform silicon machines in tasks like object recognition. Furthermore, our brain uses less energy than ...
You can do a lot in four years: go from white to black belt in taekwondo, plant a dwarf apple tree and pick its fruit, see your grandchild off to college and attend her graduation or get your own degree. But the most severe complications of diabetes--from stroke to neuropathy to amputation--can make activities like these difficult or impossible for some people.
In a new study, West Virginia University School of Public Health researchers found that taking part in a year-long diabetes-prevention program supports the addition of 4.4 quality-adjusted life-years to participants' average lifespan.
"Fatalism can play a major role in community health--like, 'Oh, yeah, my family has diabetes. I'm going to get it eventually,'" said Adam Baus, a research assistant professor ...
Alzheimer's disease shares some key similarities with healthy aging, according to a new mathematical model described today in eLife.
The model provides unique insights into the multiscale biological alterations in the elderly and neurodegenerative brain, with important implications for identifying future treatment targets for Alzheimer's disease.
Researchers developed their mathematical model using a range of biological data - from 'microscopic' information using gene activity to 'macroscopic' information about the brain's burden of toxic proteins (tau and amyloid), its neuronal function, cerebrovascular flow, metabolism and tissue structure from molecular PET and MRI scans.
"In both aging and disease research, most studies ...
A global effort to reduce sulfur and greenhouse gas (GHG) emissions from ships has researchers from the National Renewable Energy Laboratory (NREL) and other Department of Energy facilities investigating the potential use of marine biofuels.
"Biofuels turned out to be very good options because they have zero or very, very low sulfur compared to fossil fuels," said Eric Tan, a senior research engineer at NREL and lead author of a new article published in the journal Environmental Science and Technology.
His co-authors of "Biofuel Options for Marine Applications: Techno-Economic and Life-Cycle Analyses" are Ling Tao, also from NREL, along with scientists with Argonne National Laboratory, Pacific Northwest National Laboratory, ...
NEW YORK, NY (May 18, 2021) - An expert panel convened by the Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer's disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias. Their guidance was published in the May 18, 2021 issue of Neurology®, the medical journal of the American Academy of Neurology ("Value-Generating Exploratory Trials in Neurodegenerative Dementias").
These efficiencies in clinical trials can help to achieve proof of concept more rapidly and at lower costs. The estimated cost of developing ...
More than a year into the pandemic, the disproportionate burden of COVID-19 among racial and ethnic minorities in the US has been well documented. But a new study by Boston University School of Public Health (BUSPH) reveals that previous research has underestimated the true extent of racial disparities in COVID-19 deaths--as well as the extent to which structural racism contributes to these deaths.
Published in the Journal of Racial and Ethnic Health Disparities, the paper is the first to quantify the state-level differences in racial disparities in COVID-19 mortality among Black and White populations, using directly ...
Researchers at Tulane University School of Medicine have developed a highly sensitive blood test that can find traces of the bacteria that causes tuberculosis (TB) in infants a year before they develop the deadly disease, according to a study published in BMC Medicine.
Using only a small blood sample, the test detects a protein secreted by Mycobacterium tuberculosis, which causes TB infection. It can screen for all forms of TB and rapidly evaluate a patient's response to treatment, said lead study author Tony Hu, PhD, Weatherhead Presidential Chair in Biotechnology Innovation at Tulane University.
"This is a breakthrough for infants with tuberculosis because ...
A new cancer vaccine could boost the positive effects of existing immunotherapy drugs, improving the success rate of treatments from 20% to 75% of cases, according to a new study by immunologists from the University of Konstanz. The vaccine, which incorporates a new immunostimulant that is safe for use in humans, was shown to partially eliminate tumours in mice. However, the study further demonstrated that combining the vaccine with an immune checkpoint inhibitor -- an established immunotherapy drug with a 20% success rate overall for patients -- can vastly ...
Climate change induced yield reductions can be compensated by cultivar adaptation and global production can even be increased.
Global agriculture both is one of the major drivers of climate change and strongly affected by it. Rising temperatures are among the main reasons for yield reductions. Therefore, the agricultural sector is faced with the major challenge of adapting to climate change in order to ensure food security in the future. According to a new study carried out by international researchers, the use of locally adapted cultivars can significantly contribute to achieve this goal. The study ...
